Stock Events

Senseonics 

€0.33
331
+€0.01+4.54% Friday 06:08

Statistics

Day High
0.33
Day Low
0.33
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
185.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovConfirmed
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.04
-0.03
-0.01
0
Expected EPS
-0.0275
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6L6.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap27.95B
Dexcom produces continuous glucose monitoring systems for diabetes management, directly competing with Senseonics' Eversense CGM system.
Abbott Laboratories
ABT
Mkt Cap189.14B
Abbott Laboratories offers the FreeStyle Libre, a flash glucose monitoring system, competing in the glucose monitoring space.
Tandem Diabetes Care
TNDM
Mkt Cap2.45B
Tandem Diabetes Care manufactures insulin pumps and integrated diabetes management systems, competing in the broader diabetes management market.
Insulet
PODD
Mkt Cap12.76B
Insulet Corporation develops the Omnipod, an insulin management system, which competes with diabetes management solutions like Senseonics'.
Medtronic
MDT
Mkt Cap105.2B
Medtronic offers the Guardian Sensor 3 CGM and insulin pumps, providing integrated diabetes management solutions.
Mirum Pharmaceuticals
MIRM
Mkt Cap1.91B
Mirum Pharmaceuticals, though more focused on liver diseases, has interests in metabolic disorders, potentially overlapping with diabetes management.
Novo Nordisk
NVO
Mkt Cap452.48B
Novo Nordisk specializes in diabetes care with insulin and GLP-1 receptor agonists, indirectly competing in diabetes management.
Sanofi
SNY
Mkt Cap132.87B
Sanofi produces insulin and other diabetes medications, competing in the broader market for diabetes management.
Merck
MRK
Mkt Cap290.13B
Merck & Co., with its diabetes medication portfolio, including Glucophage, competes in the pharmaceutical management of diabetes.
Bristol-Myers Squibb
BMY
Mkt Cap94.72B
Bristol-Myers Squibb, through its metabolic disorders treatment portfolio, indirectly competes in the diabetes management space.

About

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Show more...
CEO
Dr. Timothy T. Goodnow Ph.D.
Employees
132
Country
US
ISIN
US81727U1051
WKN
000A2AGQW

Listings